Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell
Michihisa Moriguchi, Kaoru Tsuchiya, Masafumi Ikeda, Yozo Sato et al.
Citations
8 citations
Journal
BMC Cancer
Topics
Hepatocellular Carcinoma Treatment and Prognosis
Field-Weighted Citation Impact (FWCI)
10.58
article
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell
Kurume University (JP), Chiba University (JP), Kanagawa Prefectural Hospital Organization (JP), Kyoto Prefectural University of Medicine (JP), Kanazawa University Hospital (JP), Fujita Health University Hospital (JP), Himeji Red Cross Hospital (JP), Aichi Cancer Center (JP), Teine Keijinkai Hospital (JP), National Cancer Center Hospital East (JP), Musashino Red Cross Hospital (JP), Kanagawa Cancer Center, Nara Medical University (JP), Hyogo University (JP), Kindai University (JP), The University of Osaka (JP)